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Abstract 
Background: Databases for gene variants are very useful for sharing genetic data and to facilitate the understand‑
ing of the genetic basis of diseases. This report summarises the issues surrounding the development of the Malaysian 
Human Variome Project Country Node. The focus is on human germline variants. Somatic variants, mitochondrial 
variants and other types of genetic variation have corresponding databases which are not covered here, as they have 
specific issues that do not necessarily apply to germline variations.
Results: The ethical, legal, social issues, intellectual property, ownership of the data, information technology imple‑
mentation, and efforts to improve the standards and systems used in data sharing are discussed.
Conclusion: An overarching framework such as provided by the Human Variome Project to co‑ordinate activities 
is invaluable. Country Nodes, such as MyHVP, enable human gene variation associated with human diseases to be 
collected, stored and shared by all disciplines (clinicians, molecular biologists, pathologists, bioinformaticians) for a 
consistent interpretation of genetic variants locally and across the world.
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Background
The management of inherited diseases are a major prob-
lem in the health care system. In addition to the complex-
ity and heterogeneity of the clinical data, patients who 
receive treatment from multiple care centres also cause 
the fragmentation of important information regarding 
the diseases. The creation of databases that allow com-
prehensive access to basic clinical and genetic data will 
greatly improve accurate diagnosis and treatment of 
patients with genetic disorders.
The Human Variome Project is an international non-
governmental organisation working to build capacity in 
the practice of responsible genomics. To ensure that this 
contributes to improving global health outcomes, The 
Human Variome Project focusses on increasing both the 
quality and quantity of genomic knowledge that is col-
lected, curated, interpreted and shared for clinical prac-
tice. The Human Variome Project acts as an umbrella 
organisation across multiple countries, institutions and 
initiatives to establish collaboration around its central 
vision—the responsible, free and open online publishing 
of variants and associated clinical data and other infor-
mation to assist interpretation of variants.
The systematic collection of human genetic variation 
is an ambitious goal with vast technical and organiza-
tional challenges, which must take into account the dif-
fering ethical, legal and social norms that exist across the 
world. The Human Variome Project proposes two main 
mechanisms to meet the challenges of free and respon-
sible sharing of genetic variant information pertaining 
to human disease. One is to assist countries in develop-
ing their own capacity to generate and contribute their 
own variant information via the establishment of HVP 
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Country Nodes. The other is to support international 
groups formed around specific genes or diseases to do 
the same [1].
HVP Country Nodes are a vital component for achiev-
ing improved health outcomes for people both within 
the country and around the world. An HVP Country 
Node is defined as having three components: (1) A cen-
tral repository or network of databases, that receive and 
store information on variation in the human genome 
that has been generated within each country to enable 
the sharing of that information both nationally and 
internationally; (2) a governance structure that ensures 
that the work of the Node is both sustainable in the long 
term and is consistent with all relevant national and 
international ethical, legal and social requirements; and 
(3) a set of policies and procedures that ensures that the 
repository is operated and maintained in a responsible 
and accountable manner that is consistent with both 
national and HVP standards.
Gene/disease‑specific variant databases
One of the advantages of an HVP Country Node is 
the role it can play in supporting gene-disease specific 
databases. For example, the International Society for 
Gastrointestinal Hereditary Tumours (InSiGHT) is a 
professional body of healthcare workers dedicated to 
advancing knowledge and management of familial gas-
trointestinal (GI) cancer. Its mission includes the facili-
tation of international collaborative projects among its 
members, to support databases of variants related to 
familial gastrointestinal tumours, and to apply its robust 
system to assign pathogenicity status to gene variants. 
The InSiGHT DNA Mismatch Repair (MMR) data-
base [2] forms a primary store of public information of 
inherited gastrointestinal cancer gene variants and uses 
Leiden Open Variation Database (LOVD http://www.
lovd.nl/) to consolidate data from various sources such 
as published literature, diagnostic laboratory submis-
sions, clinical reports, research data, and other data-
bases [3]. DNA sequencing techniques have improved 
leading to an expanding amount of published reports 
relating to MMR genes. The shared interests between 
InSiGHT and the Human Variome Project have driven 
a substantial increase in submissions of MMR variants 
to the central database. Major outcome of the pilot 
project initiated by InSiGHT and the Human Variome 
Project was the establishment of Gene/Disease Specific 
Databases (GDSDb) as an integral part of the Human 
Variome Project vision. The formation of GDSDb is to 
allow gene/disease specialists to value-add to the data 
collected in Country Nodes such as providing expert 
interpretation of variant effects.
National databases
A number of countries have established nationwide 
efforts to collect genetic variant data. The Australian 
Node of the Human Variome Project was the first offi-
cial HVP Country Node, established in Australia in 2009. 
Funded by the Australian federal government, the pro-
ject played a role in installing and testing a data collec-
tion system in diagnostic laboratories. The initial phase 
was completed in mid-2011 and the data was made 
accessible to researchers, clinicians and diagnostic labs 
throughout the country. The Australian Node does not 
currently share data internationally. In China, by using 
the LOVD platform, the Centre for Genetic and Genomic 
Medicine has begun their data collection in collaboration 
with healthcare industry, basic research organisations, 
and industry partners. In the United Kingdom, using 
proprietary software, the Diagnostic Mutation Database 
(DMuDb http://www.ngrl.org.uk/Manchester/dmudb.
html) was formed to collect data directly from diagnos-
tic laboratories. A Consortium of Arab Genetics Socie-
ties (CAGS) developed a database of disease diagnosed 
in Arab populations [4]. In France, the Universal Muta-
tion Database (UMD http://www.umd.be) has served as 
a central store for genetic data produced in a network of 
French laboratories. The UMD software is tailored spe-
cifically for a variety of genes associated with cancer and 
genetic diseases [5].
Endeavours to centralise genetic variants does not 
necessarily follow national boundaries or disease priori-
ties. For example, the Faroe Islands, with a population of 
50,000 has planned on sequencing the entire population 
[6]. This will expand the focus from a small number of 
highly prevalent diseases in the Faroes, to a more com-
prehensive approach that will bring personalised medi-
cine based on each individual’s genetic sequence.
Genome‑wide variant databases
The other main type of variant database are large central-
ised collections of variants from all genes in the genome. 
One of the earliest and most well-known is dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP), which collates vari-
ants from humans and other organisms [7]. It’s collection 
of variants is not limited by disease-association or other 
criteria, so it is a clearing-house for all types of variation. 
ClinVar is a recent initiative of the National Center for 
Biotechnology Information (NCBI) to centralise variants 
from submitting organisations, particularly information 
from diagnostic laboratories. It aims to display the asser-
tions regarding the variant’s impact on phenotype, and 
provides free access to the data. The Human Gene Muta-
tion Database (HGMD) collates genetic variants from 
published literature. It is available to registered users in 
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free and commercial versions—with the paid subscrip-
tion providing the most updated data [8].
Initiating an HVP country node: the Malaysian 
experience
The Malaysian Human Variome Project (MyHVP) (http://
hvpmalaysia.kk.usm.my/) was launched on the 9th Octo-
ber 2010. To date, 71 individuals from 12 Malaysian 
universities and academic institutions form the mem-
bership of MyHVP. MyHVP has succeeded in develop-
ing an online portal for the mutation of genes related to 
genetic diseases prevalent in Malaysia and also the Malay 
whole genome SNP data. MyHVP marks a new horizon 
for genetic activities in Malaysia and provides a database 
on genetic variation that relates to the Malaysian popula-
tion. The most recent development is the establishment 
of the Southeast Asia (SEA) regional node of the Human 
Variome Project (HVP SEA Node), which is expected to 
bring together individuals working in diagnostics and 
clinical care within Malaysia and Southeast Asia (SEA). 
The HVP SEA Node was established through Malaysia’s 
position as the regional role model in genomic research 
and diagnostic services especially for Southeast Asian 
developing countries. It is believed that the formation of 
MyHVP will be able to assist these countries by provid-
ing training and education in order to increase public 
awareness on the importance of genetics and genomics 
in health care. By emphasizing the four areas of activities 
for the Human Variome Project which are setting nor-
mative functions, behaving ethically, sharing knowledge 
and building capacity, MyHVP will ultimately be a refer-
ral center for SEA variome activities. This will elevate the 
status, enhance the visibility and highlight the contribu-
tions of Malaysia in the field of genetics, genomics and 
variomics.
Administrative activities of a country node
There are diverse issues that needed to be considered 
in the formation of HVP Country Node: medical and 
genetic information privacy, Information Technology, 
Ethical/Legal/Social Issues, (ELSI), and organisational 
structure. A wide variety of expertise and co-operation 
between different groups is required to successfully 
implement a country node. The critical component in 
the initiation and development of the Country Node is a 
local well-informed and enthusiastic champion to drive 
the project forward. Most importantly, an HVP Country 
Node should be formed in association with the respec-
tive local human genetics/genomics society. Therefore, 
the formation of MyHVP received full support not only 
from the highest administration level of the university, 
but also from local societies such as Genetics Society of 
Malaysia, the Malaysian Society of Human Genetics, the 
Medical Genetics Society of Malaysia, and the Malay-
sian Society of Bioinformatics and Computational Biol-
ogy. The Malaysian Ministry of Sciences, Technology 
and Innovation (MOSTI) and Ministry of Education 
(MOE) supported the project at several government lev-
els including the Malaysian Ambassador to UNESCO. 
Creating an HVP Country Node also requires support 
from diverse stakeholders, from patient advocacy groups 
through local and national government agencies. MyHVP 
received the funding from Universiti Sains Malaysia 
through APEX Grant (1002/PPSP/910343) with the 
amount RM790,959.32 since November 2012 to set up 
the MyHVP Country Node. This amount is for advocacy 
of MyHVP and genomic research such as the sequenc-
ing project for the Malay ethnicities. At the administra-
tive level, support from clinicians, diagnostic personnel, 
geneticists, bioinformaticians and other important stake-
holders within the country has helped in initiating and 
sustaining the project.
The ICT infrastructure system
The Malaysian Node of the Human Variome Project 
(MyHVP) Database used open source software in the 
development of the variation and mutation databases. 
The database was created to organise, store and distrib-
ute variations and mutations that are related to popula-
tion specific Malaysian ethnic groups. The following 
freely available open source software uses the PHP script-
ing language v.4.2.0 and up (http://www.php.net), and 
MySQL database package v.3.23.33 and up (http://www.
mysql.com). The MyHVP Database has been constructed 
based on a three-tier architecture model i.e. client, web 
and database. PHP scripts are used as a common gateway 
interface (CGI) for sending and receiving data between 
the front end user/client and the database server. To 
query data, users need to enter or choose a keyword 
such as SNP ID or chromosome number or Gene ID. The 
Apache web server then transforms the query into SQL 
for it to be requested from MySQL database.
In addition, MyHVP is planning to implement an LOVD 
system, which is also written in PHP and uses MySQL 
open source software. It was developed to allow the easy 
creation and maintenance of a gene sequence variation 
database using the internet. The gene-centred design of 
the database follows the recommendations of the Human 
Genome Variation Society (HGVS http://www.hgvs.
org/) and focuses on ease of use and flexibility. The new-
est LOVD version 3, released late 2012, also allows storage 
of Massively-Parallel Sequencing data, which often results 
in large numbers of variants found in between genes as 
well. To ensure the use of unambiguous sequence variant 
descriptions in newly submitted data, LOVD interacts with 
Mutalyzer [9] to apply the HGVS human nomenclature 
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guidelines to check and enforce correct sequence variant 
descriptions. The usual focus of LOVD is the connection 
between a gene and a heritable disease. Sequence variants 
found in individuals are imported or submitted into the 
database, together with information about whether they 
could be causally related to the disease. Specialized doc-
tors (clinical geneticists) can use LOVD disease specific 
databases to assist in interpreting diagnostic sequencing 
data and advise patients confirmed as carrying a genetic 
disease. Ideally, if a patient has been screened for muta-
tions and one has been found, information in LOVD can 
assist in the diagnosis and progress of this disease. By typ-
ing genesymbol.lovd.nl onto one’s browser, the user will be 
connected directly to the web browser and LOVD data-
base displaying a list of choices for the corresponding gene.
Ethical/legal/social issues (ELSI)
An important aspect of the development of a Country 
Node is the multicultural, ethical and legal issues that 
might contribute to problems in submitting the genetic 
data. MyHVP will endeavour to resolve these questions 
over time as they develop in the Malaysian context. 
Among the issues analysed is whether one has a right to 
know or a right not to know genetic information. This is 
in line with the UNESCO Universal Declaration on the 
Human Genome and Human Rights which states in Arti-
cle 5c the right of every individual to choose whether or 
not to be informed of the results and consequences. Cur-
rently, there exists no regulatory framework that control 
genetic testing, screening and gene therapy in Malaysia.
Obtaining consent from human subjects and patients is 
crucial to any medical testing and research. A survey of 
research institutes in Malaysia has revealed that there is 
no standard form and practice in obtaining consent from 
human subjects. Yet obtaining effective consent from 
human subjects is key defence to any possible allegation 
of medical malpractice.
Malaysia’s population comprises many ethnic groups, 
whereby the total population is 28.3 million, with the 
Malays comprised 63  % of the total population, fol-
lowed by Chinese (28 %), Indians (8 %), and other ethnic 
groups (1  %) [10]. Most of them are actually descended 
from Javanese, Bugis, and Minang sailors who came from 
Indonesia, during the 17th to early 20th centuries. The 
vast majority of ethnic Malaysian Chinese came from 
the Fujian and Guangdong provinces in Southern China. 
Malaysian Indians are a group of Malaysians largely 
descended from those who migrated from southern India 
during the British colonization of Malaya.
The wide genetic variation produced from the mul-
tiracial population will enable researchers to conduct 
comparative studies between matched cohorts with and 
without disease. Discovering these variations will provide 
fundamental new insight into the pathogenesis, diagnosis 
and treatment of human diseases and towards the devel-
opment of personalized medicine. Thus, besides being 
responsible for the funding, collection and data storage, 
each Country Node needs to ensure the handling of the 
data is according to the nation’s own law in an ethical and 
culturally sensitive manner. To alleviate patients’ privacy 
issues in relation to the database records, the curator 
needs to have clear guidelines to solve the challenges. The 
ethical issues in the data-basing of mutations have been 
discussed seriously especially in the Islamic perspec-
tive and recent attempts have been made to tailor some 
important guidelines from UNESCO, HUGO and WHO 
that can fit the local curating of phenotype/genotype data 
[11, 12].
Another issue that surrounds the use of genetic data is 
when genetic information is taken from corpses. The issue 
that arises would be the prior informed consent of the fam-
ily concerned which gives rise to the question of ownership 
of the corpse. This is an active area for research in terms of 
genealogy and paternity testing but also in the genetics of 
diseases. At this juncture, it is important to look into the 
Islamic position which places due respect on the dead and 
the rights owed to them and a consideration will need to 
be made as to whether the collection of genetic informa-
tion from dead bodies is against the Islamic Law.
Medical/genetic confidentiality
Collection of DNA samples from live donors implicates 
confidentiality issues. The medical data is considered to 
be sensitive data and has raised an argument that any 
form of DNA sampling and collection would also have to 
comply with the personal data principles. Therefore, the 
handling of such data requires extreme care and explore 
other duties of confidentiality that may arise from com-
mon law and other statutory instruments such as Medi-
cal Act 1971, Private Healthcare Facilities and Services 
Act 1998, Child Act 2001. What other usage could a 
researcher/doctor make of medical/genetic data with-
out offending the data privacy principles? On a broader 
scale, the collection of DNA samples could also implicate 
privacy issues. With the enactment of the Personal Data 
Protection Act 2010 [13], there is a wide exception given 
for research. However, would the possible aim of devel-
oping commercial applications to the research output 
exclude these activities from the research exception? This 
is not made clear in the Act.
MyHVP data collection results
In the MyHVP Database, the Malay ethnic group has been 
the first to have available online the 291,718 SNPs dataset 
which was obtained by genotyping the SNPs of 103 healthy 
individuals from Champa, Kelantan, Bugis, Banjar, Kedah 
Page 5 of 7Nik Hassan et al. BMC Res Notes  (2016) 9:125 
and Jawa subgroups of Malays. The mutation database also 
includes 143 mutations from 16 genes related to diseases 
common in the Malay ethnic group. However, the number 
of mutations will be increasing as there are on-going stud-
ies on disease causing variants. In fact, MyHVP database 
has curators who are responsible to add new mutations 
monthly. The current data on these mutations was collected 
from results published in journals [14]. All mutational data 
in the MyHVP database were recorded based on the Human 
Genome Variation Society (HGVS) nomenclature (http://
Fig. 1 Data structures that were recorded in the MyHVPDb
Table 1 Sequence variants according to the Human Genome Variation Society(HGVS) (http://www.hgvs.org/mutnomen/
standards.html)
Variants Description
DNA/RNA  Conversion = a sequence change where a range of nucleotides are replaced by a sequence from  Elsewhere in the genome
 Deletion = a sequence change where one or more nucleotides are removed (deleted)
 Deletion/insertion (indel) = a sequence change where one or more nucleotides are replaced by one or More other nucleotides
  Note: when one nucleotide is replaced by one other nucleotide the change is called a substitution
 Duplication = a sequence change where a copy of one or more nucleotides are inserted directly 3’‑ flanking of the original copy
Note: when the copied sequence is not inserted directly 3’‑flanking of the original copy the
change is called an insertion
 Insertion = a sequence change where one or more nucleotides are inserted between two nucleotides but where the insertion is 
not a copy of a sequence immediately 5’‑flanking (see duplication)
 Inversion = a sequence change where more than one nucleotide replacing the original sequence are the  reverse complement of 
the original sequence
 Substitution = a sequence change where one nucleotide is replaced by one other nucleotide
 Note: a sequence change where one nucleotide is replaced by more than one other
nucleotide is a deletion‑insertion (indel)
Note: a sequence change where more than one nucleotide is replaced by one or more
other nucleotide is a deletion‑insertion (indel)
Characters used: (1) Reference sequences
c. = coding DNA reference sequence
(2) Numbering
I. Genomic, mitochondrial, non‑coding RNA, RNA and protein reference sequence
N = nucleotide N in reference sequence (e.g. 311A > G)
II. coding DNA reference sequence
N = nucleotide N in protein coding sequence (e.g. 11A > G)




 > (greater than) = changes to (substitution)
c.5T > G substitution
4) Others
 chr = chromosome (e.g. chr19 or chrX)
 del = deletion
 dup = duplication
 ext = extension (e.g. N‑ or C‑terminus of protein)
 ins = insertion
 inv = inversion
 con = (gene) conversion
 fs = frame shift
 t = translocation
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www.hgvs.org/mutnomen/standards.html) (Fig. 1). Detailed 
description of sequence variants is at the Table 1.
Summary
Collaboration with national and international experts 
will facilitate the free and open sharing of annotated and 
curated information. By following the experiences of 
InSiGHT, the Australian Node of the Human Variome 
Project and other databases, new processes and systems 
are under development at MyHVP which are adapted to 
Malaysian legal and ethical frameworks. A new version 
of LOVD known as LOVD v3 which is available online 
will enable more complex data submissions. With the 
increasing number of data entries in future, the database 
user interface will be further developed to allow for much 
easier navigation and customized display of database 
query results. It is hoped that this article will encourage 
the systematic integration of variant submission in nor-
mal laboratory practice.
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